COVID-19 vaccination in pregnant and lactating women
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.023Keywords
vaccination, COVID-19, pregnant women, lactating womenAbstract
Introduction: The COVID-19 pandemic significantly changed the lifestyle of pregnant women. Pregnant women with COVID-19 are more likely to suffer from severe disease, as well as unfavorable pregnancy and childbirth. Currently, there is no causal treatment for this disease available, so attention should be paid to preventing infection with vaccines.
Aim of the study: A review of the literature on the influence of COVID-19 vaccines on the course of pregnancy and summary of recommendations regarding the use of COVID-19 vaccines during pregnancy and breastfeeding.
State of knwoledge: Three types of COVID-19 vaccines are most commonly used: mRNA vaccines, vector vaccines as well as subunit vaccines. In preclinical developmental and reproductive toxicity studies in animal models, there were no alarming safety signals, and observations of vaccinated pregnant women did not reveal any complications with respect to the course of pregnancy and development of the fetus. No cases of neonatal death have been reported in the first 28 days after birth. Most of the side effects following vaccination, such as injection site pain or tenderness, fatigue, fever or muscle pain, were moderate and resolved within 24 hours. The current research results confirm a positive immune response in pregnant women. Moreover, it is important that the presence of antibodies in the umbilical cord blood makes it possible to protect and reduce the risk of SARS-CoV-2 infection of the newborn.
Summary: All pregnant women, irrespective of trimester, and breastfeeding mothers are advised to administer a booster dose of the COVID-19 vaccine within an appropriate period of time after the primary vaccination schedule.
References
Allotey, J., Fernandez, S., Bonet, M., Stallings, E., Yap, M., Kew, T., Zhou, D., Coomar, D., Sheikh, J., Lawson, H., Ansari, K., Attarde, S., Littmoden, M., Banjoko, A., Barry, K., Akande, O., Sambamoorthi, D., van Wely, M., van Leeuwen, E., Kostova, E., Kunst, H., Khalil, A., Tiberi, S., Brizuela, V., Broutet, N., Kara, E., Kim, C.R., Thorson, A., Escuriet, R., Gottlieb, S., Tong, V.T., Ellington, S., Oladapo, O.T., Mofenson, L., Zamora, J., Thangaratinam, S., Clinicalmanifestations, riskfactors, and maternal and perinataloutcomes of coronavirusdisease 2019 inpregnancy: livingsystematicreview and meta-analysis. BMJ. 2020; m3320.
Ewer, K., Sebastian, S., Spencer, A.J., Gilbert, S., Hill, A.V.S., Lambe, T., Chimpanzee adenoviral vectors as vaccines for out break pathogens. HumanVaccines&Immunotherapeutics. 2017; 13, 3020–3032. https://doi.org/10.1080/21645515.2017.1383575
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J.N., Port, J.R., Avanzato, V.A., Bushmaker, T., Flaxman, A., Ulaszewska, M., Feldmann, F., Allen, E.R., Sharpe, H., Schulz, J., Holbrook, M., Okumura, A., Meade-White, K., Pérez-Pérez, L., Edwards, N.J., Wright, D., Bissett, C., Gilbride, C., Williamson, B.N., Rosenke, R., Long, D., Ishwarbhai, A., Kailath, R., Rose, L., Morris, S., Powers, C., Lovaglio, J., Hanley, P.W., Scott, D., Saturday, G., de Wit, E., Gilbert, S.C., Munster, V.J., ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia In rhesusmacaques. Nature. 2020; 586, 578–582. https://doi.org/10.1038/s41586-020-2608-y
Wold, W., Toth, K., AdenovirusVectors for GeneTherapy, Vaccination and CancerGeneTherapy. CGT. 2020; 13, 421–433. https://doi.org/10.2174/1566523213666131125095046
Centres for Disease Control and Prevention a, Understanding mRNA COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html, 2021, [data dostępu: 05.08.2022].
Krammer, F., SARS-CoV-2 vaccinesin development. Nature. 2020; 586, 516–527. https://doi.org/10.1038/s41586-020-2798-3
Pardi, N., Hogan, M.J., Porter, F.W., Weissman, D., mRNAvaccines — a new era invaccinology. Nat RevDrugDiscov. 2018; 17, 261–279. https://doi.org/10.1038/nrd.2017.243
Chmielewska A., 2020. Czy szczepionki wektorowe lub mRNA przeciwko COVID-19 mogą modyfikować genom osoby zaszczepionej? [WWW Document]. URL https://www.mp.pl/szczepienia/ekspert/ekspert-covid-19/254920,czy-szczepionki-wektorowe-lub-mrna-przeciwko-covid-19-moga-modyfikowac-genom-osoby-zaszczepionej [data dostępu: 05.08.2022].
EuropeanSociety of HumanReproduction and Embryology, 2021, COVID-19 vaccination and assistedreproduction. [WWW Document]. URL COVID-19 vaccination and assistedreproduction, SARSCOV2%20and%20service%20adaptation_08June2021%20(1).pdf [data dostępu: 12.01.2021].
U.S. Food and DrugAdministration a, 2021, FactSheet for Healthcare ProvidersAdministeringVaccine [WWW Document]. URL https://www.fda.gov/media/146304/download [data dostępu: 05.08.2022].
Europejska Agencja Leków (EMA), 2021, Charakterystyka produktu leczniczego, [WWW Document]. URL https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_pl.pdf [data dostępu: 11.03.2021].
U.S. Food and DrugAdministration b, 2021, Vaccines and RelatedBiological Products AdvisoryCommitteeMeeting [WWW Document]. URL https://www.fda.gov/media/146219/download [data dostępu: 05.08.2022).
U.S. Food and DrugAdministration c, Vaccines and RelatedBiological Products AdvisoryCommitteeMeeting, [WWW Document], 2021, URL https://www.fda.gov/media/144434/download[data dostępu: 05.08.2022].
Komisja Europejska a, 2020, Comirnaty, INN-COVID-19 mRNAVaccine (nucleoside-modified) [WWW Document]. URL https://ec.europa.eu/health/documents/community-register/2020/20201221150522/anx_150522_pl.pdf[data dostępu: 05.08.2022].
Komisja Europejska b, 2020, COVID-19 VaccineAstraZeneca, COVID-19 Vaccine (ChAdOx1-S) [WWW Document]. URL https://ec.europa.eu/health/documents/community-register/2021/20210129150842/anx_150842_pl.pdf[data dostępu: 05.08.2022].
The American College of Obstetricians and Gynecologists a, 2021, COVID-19 VaccinationConsiderations for Obstetric–GynecologicCare [WWW Document]. URL https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf[data dostępu: 05.08.2022].
U.S. Food and DrugAdministration d, 2020, Vaccines and RelatedBiological Products AdvisoryCommittee [WWW Document]. URL https://www.fda.gov/media/144245/download[data dostępu: 05.08.2022].
U.S. Food and DrugAdministration e, 2021, Vaccines and RelatedBiological Products AdvisoryCommittee [WWW Document]. URL https://www.fda.gov/media/146217/download, 2021[data dostępu: 05.08.2022].
Centers for DiseaseControl and Prevention b
, V-safe COVID-19 VaccinePregnancy Registry.https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafepregnancyregistry.html[data dostępu: 05.08.2022].
Centers for DiseaseControl and Prevention c, 2021. COVID-19 vaccinesafetyupdate. [WWW Document]. URL https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/28-03-01/05-covid-Shimabukuro.pdf[data dostępu: 05.05.2022].
Kadali, R.A.K., Janagama, R., Peruru, S.R., Racherla, S., Tirumala, R., Madathala, R.R., Gajula, V., Adverseeffects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectionalstudy on health care Wolkers with detailed self-reporteds ymptoms. American Journal of Obstetrics and Gynecology. 2021; 225, 458–460. https://doi.org/10.1016/j.ajog.2021.06.007
Medicines and Healthcare products Regulatory Agency, 2021. Public Assessment Report [WWW Document]. URL https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19 [data dostępu: 05.08.2022].
Zauche, L.H., Wallace, B., Smoots, A.N., Olson, C.K., Oduyebo, T., Kim, S.Y., Peterson, E.E., Ju, J., Beauregard, J., Wilcox, A.J., Rose, C.E., Meaney-Delman, D., Ellington, S.R, Receipt of mRNA COVID-19 vaccines preconception and Turing pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21 (preprint). In Review. https://doi.org/10.21203/rs.3.rs-798175/v1
Hardy-Fairbanks, A.J., Pan, S.J., Decker, M.D., Johnson, D.R., Greenberg, D.P., Kirkland, K.B., Talbot, E.A., Bernstein, H.H., ImmuneResponsesinInfantsWhoseMothersReceivedTdapVaccineDuringPregnancy. PediatricInfectiousDiseaseJournal. 2013; 32, 1257–1260. https://doi.org/10.1097/INF.0b013e3182a09b6a
Walls, T., Graham, P., Petousis-Harris, H., Hill, L., Austin, N., Infant outcomesafterexposure to Tdapvaccineinpregnancy: an observationalstudy. BMJ Open. 2016; 6, e009536. https://doi.org/10.1136/bmjopen-2015-009536
Baxter, R., Bartlett, J., Fireman, B., Lewis, E., Klein, N.P., Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics. 2017; 139, e20164091. https://doi.org/10.1542/peds.2016-4091
Centers for Disease Control and Prevention d, 2021. Vaccines During pregnancy FAQs. [WWW Document]. URL https://www.cdc.gov/vaccinesafety/concerns/vaccines-during-pregnancy.html[data dostępu: 05.08.2022].
Paul, G., Chad, R. Newborn antibodies to SARS-CoV-2 detected in cord blond after Materna vaccination – a case report. BMC Pediatr. 2021; 21, 138. https://doi.org/10.1186/s12887-021-02618-y
Beharier, O., PlitmanMayo, R., Raz, T., NahumSacks, K., Schreiber, L., Suissa-Cohen, Y., Chen, R., Gomez-Tolub, R., Hadar, E., Gabbay-Benziv, R., JaffeMoshkovich, Y., Biron-Shental, T., Shechter-Maor, G., Farladansky-Gershnabel, S., YitzhakSela, H., Benyamini-Raischer, H., Sela, N.D., Goldman-Wohl, D., Shulman, Z., Many, A., Barr, H., Yagel, S., Neeman, M., Kovo, M., Efficien tmaternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. Journal of Clinical Investigation, 2021; 131, e150319. https://doi.org/10.1172/JCI150319
Gray, K.J., Bordt, E.A., Atyeo, C., Deriso, E., Akinwunmi, B., Young, N., Baez, A.M., Shook, L.L., Cvrk, D., James, K., De Guzman, R., Brigida, S., Diouf, K., Goldfarb, I., Bebell, L.M., Yonker, L.M., Fasano, A., Rabi, S.A., Elovitz, M.A., Alter, G., Edlow, A.G., Coronavirus disease 2019 vaccine response in pregnant and lactating women: a kohort study. American Journal of Obstetrics and Gynecology, 2021; 225, 303.e1-303.e17. https://doi.org/10.1016/j.ajog.2021.03.023
The American College of Obstetricians and Gynecologists b, 2021. COVID-19 VaccinationConsiderations for Obstetric–GynecologicCare. [WWW Document]. URL https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care[data dostępu: 05.08.2022].
Centers for DiseaseControl and Prevention e, 2021. Interim ClinicalConsiderations for Use of COVID-19 VaccinesCurrentlyApprovedorAuthorizedinthe United States. [WWW Document]. URL https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-considerations.html[data dostępu: 05.08.2022].
Government of Jersey, 2021. Vaccineinformation for COVID-19 [WWW Document]. URLhttps://www.gov.je/Health/Coronavirus/Vaccine/Pages/COVID19VaccineInformation.aspx#anchor-5[data dostępu: 05.08.2022].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Karolina Kaziród, Weronika Kuryło, Kinga Brzuszkiewicz, Andrzej Miturski, Anna Semczuk-Sikora
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 319
Number of citations: 0
